Eli Lilly shares first human trial results for LOXO-435, a selective FGFR3 inhibitor for bladder cancer, showing 41% response ...

WashU Medicine-led trial evaluating investigational drug from Eli Lilly and Company aims to stop disease before symptoms ...

Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s,” Charles Piller looks how the amyloid hypothesis took over ...

Growing demand for tryptamine APIs stems from their anti-cancer potential, pharmaceutical uses, and role as a neurotransmitter modulator i ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly & Company Chairman and CEO Dave Ricks sheds light on growth and success, the increase in weight loss drug ...

1 Division of Endocrinology, CSIR-Central Drug Research Institute, Lucknow, India 2 Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India Introduction: Recent interest in sperm ...

HENDERSON, Nev., Jan. 30, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the results of a large-scale study which ...

With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co. (NYSE: LLY) was another key pharma player in this new type of treatment for diabetes and obesity.

Not long after reporting phase 2 data for one of its obesity candidates that appeared to put it on par with Eli Lilly’s Zepbound, Kailera Therapeutics is preparing for an eventual market launch ...